Will RWD Get Real In Japan? Govt Moves To Build Digital Health Records
Pharma Benefits Down Road?
To enable broader use of clinical data in its digital health care system, Japan has kickstarted digitization measures to link all patient records to an online individual ID system. While the government aims to allow real-world data and evidence for the pharmaceutical sector in the long run, The Pink Sheet explores the reality of current projects and measures in the country.
You may also be interested in...
Japan is aiming for the betterment of pharma R&D and medical services for rare disease patients by building a database connecting genome analysis data and clinical records. While several clinical studies are planned for the next couple of years, there are also concerns around the actual trickle-down of benefits to patients and data privacy.
The data collected from wearable devices for a year will provide lifecycle data to a much long-termed study with various health data. The study will not only contribute to drug discovery and personalized healthcare by the firms in near future, but also suggests bigger goals by Japan’s healthcare industry.
Japan is forging ahead with a national project to elucidate cancer-related gene alterations in its population, both to identify responder patients for possible inclusion in clinical trials for targeted therapies and to inform the development of new treatments.